Status:
COMPLETED
Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Diabetic Peripheral Neuropathy
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to 1) provide continued pregabalin treatment for 6 additional months to patients who have taken part in the placebo controlled study A0081060; and 2) find out if pregabali...
Eligibility Criteria
Inclusion
- Adults with Type 1 or 2 diabetes
- Patients must have pain in their lower legs or feet due to painful diabetic neuropathy that has lasted for at least 3 months
Exclusion
- Patients must not be in poor or unstable health.
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
End Date :
May 1 2006
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00159731
Start Date
January 1 2005
End Date
May 1 2006
Last Update
January 22 2021
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Hot Springs, Arkansas, United States, 71913
2
Pfizer Investigational Site
La Jolla, California, United States, 92037
3
Pfizer Investigational Site
Torrance, California, United States, 90502
4
Pfizer Investigational Site
Torrance, California, United States, 90509